What ZORYVE cream’s infant indication means for non-steroidal eczema treatments
Can ZORYVE cream transform infant eczema care? Explore what this FDA filing means for non-steroidal treatment strategies today.
Pharma & Biotech
Pharma & Biotech
Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes
FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.
Pharma & Biotech
AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared
AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.
Pharma & Biotech
How OrganaBio’s RxMP partnership could advance RMP-402 for severe bleeding control
Find out how OrganaBio’s RxMP partnership could advance RMP-402, a first-in-class therapy for severe bleeding control.
Pharma & Biotech
Acadia Pharmaceuticals broadens Rett syndrome treatment flexibility with DAYBUE STIX rollout in the United States
Acadia Pharmaceuticals has launched DAYBUE STIX for Rett syndrome in the U.S. Read what this means for adoption, tolerability, and market strategy.
Pharma & Biotech
Why CTIS is betting FDA’s E2B(R3) deadline will reshape pharmacovigilance software demand;
CTIS launches Trial SafetyXchange to help pharma firms meet the FDA E2B(R3) deadline. Read what it changes for safety reporting teams.
Pharma & Biotech
Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.
Pharma & Biotech
Can Drug Farm turn ALPK1 inhibition into the first real disease-modifying approach for ROSAH syndrome?
Drug Farm won FDA orphan drug designation for DF-003 in ROSAH syndrome. Read what this rare disease milestone could change next.
Pharma & Biotech
Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground
FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.
Pharma & Biotech
How Glenmark Pharmaceuticals’ fluticasone inhaler approval could reshape the U.S. asthma inhaler market
Glenmark Pharmaceuticals wins FDA approval for generic fluticasone inhaler with 180-day exclusivity. Read what it means for the U.S. asthma drug market.